<DOC>
	<DOCNO>NCT02945033</DOCNO>
	<brief_summary>Four retrospective study recently publish efficacy aspirin patient surgically resect colon cancer . Two study strongly suggest aspirin use low dos ( 100 mg/d ) surgical resection colorectal cancer PI3K mutation could act target therapy major protective effect risk recurrence . The two study confirm benefit aspirin situation . These four retrospective study provide insufficient level evidence demonstrate benefit low-dose aspirin adjuvant surgery colorectal cancer . Therefore , necessary recommend conclusion study meta-analyses perform randomise prospective study validate data .</brief_summary>
	<brief_title>Study Aspirin Versus Placebo Resected Colon Cancer With PI3K Mutation Stage III II High Risk</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Age ≥ 18 year Colonic adenocarcinoma stage III Colonic adenocarcinoma stage II high risk MSS : T4bN0 T4aN0 tumour penetrate surface visceral peritoneum le 12 node evaluate ; least two follow criterion : lymphatic involvement , perineural invasion , venous invasion diagnosis bowel obstruction perforation ; poor differentiate tumour . PI3K mutation , exon 9 20 ( tumour ) Resection R0 WHO performance status 02 Chest abdominal CT scan ≤ 8 week Life expectancy ≥ 3 year Written consent sign Anticoagulant and/or Antiaggregating treatment include clopidogrel Regular aspirin use ( &gt; 3 dos per week 3 month last year ) Contraindication Aspirin : Allergy aspirin , Active antecedent peptic ulcer Severe renal hepatic insufficiency Pregnancy nursing ongoing Rectal cancer Hereditary form ( i.e . lynch syndrome patient ) Followup patient feasible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pi3k mutation</keyword>
	<keyword>Aspirin</keyword>
</DOC>